Welcome to our dedicated page for Organogenesis Hldgs SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Organogenesis Holdings Inc. (ORGO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market issuer, Organogenesis submits periodic and current reports that describe its financial condition, operating results, clinical programs, governance matters, and capital structure.
Through this page, users can review Form 10-K annual reports and Form 10-Q quarterly reports, which include audited or reviewed financial statements, segment information for its regenerative medicine operations, and detailed discussions of risk factors, research and development spending, and market dynamics for its Advanced Wound Care and Surgical & Sports Medicine product categories. These filings also outline how the company reports net product revenue, operating expenses, cash and cash equivalents, and information about Series A redeemable convertible preferred stock.
Current reports on Form 8-K document material events such as quarterly earnings releases, updates on the Phase 3 randomized controlled trials of ReNu for knee osteoarthritis, plans to request or initiate a Biologics License Application (BLA), and stockholder meeting results. For example, Organogenesis has used Form 8-K to furnish press releases on ReNu clinical data, to describe its intention to pursue a BLA submission pathway, and to report the outcomes of its annual meeting, including director elections and advisory votes on executive compensation.
Investors can also use this page to track governance and capital structure disclosures, including approvals related to the potential issuance of additional Class A common stock upon conversion of Series A Convertible Preferred Stock under Nasdaq listing rules. Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify important financial metrics, clinical program updates, and regulatory milestones without reading every line of each report.
Organogenesis Holdings Inc. executive Lori Freedman updated her insider holdings following a performance share award. She acquired 43,212 shares of Class A common stock at no cost from the vesting and settlement of a performance share award, and 14,411 shares were withheld to cover related tax obligations. This amended Form 4 corrects the originally reported acquired and tax-withheld share amounts, with no other changes to the prior filing.
Organogenesis Holdings Inc. filed an initial ownership statement for Chief Accounting Officer Patrick McGuire, detailing his direct holdings of Class A common stock and related equity awards. The filing notes that some positions represent restricted stock units granted under the 2018 Equity Incentive Plan, with unvested RSUs scheduled to vest in equal annual installments on December 29, 2026, 2027 and 2028, and on February 15, 2027, 2028 and 2029.
Organogenesis Holdings Inc. provides an in‑depth look at its regenerative medicine business, focused on advanced wound care and surgical and sports medicine products like Apligraf, Dermagraft, PuraPly, NuShield, Affinity, Novachor and ReNu.
The company outlines major shifts in Medicare and CMS policy for skin substitutes, including new 2026 payment structures and the WISeR prior‑authorization model, which are already contributing to a significant year‑over‑year revenue decline in early 2026 and may pressure future utilization and profitability.
Organogenesis also highlights mixed but generally supportive Phase 3 data for its ReNu osteoarthritis program and the start of a rolling BLA, plus a long‑term lease for a new Smithfield, Rhode Island biomanufacturing facility intended to bring Dermagraft production back online and expand capacity from 2027.
Organogenesis Holdings Inc. reported record results for 2025, driven by strong growth in advanced wound care. Net product revenue for the year reached $563.0 million, up 17% from 2024, with advanced wound care contributing $531.2 million. Net income improved to $37.0 million from $0.9 million, and Adjusted EBITDA nearly doubled to $98.1 million.
In the fourth quarter of 2025, net product revenue rose 78% to $225.1 million, and net income jumped to $43.7 million. Gross margin remained strong at 76% for the year. The company ended 2025 with $94.3 million in cash, cash equivalents and restricted cash and no outstanding debt obligations.
For 2026, management expects total net revenue between $350.0 million and $420.0 million, a decline of 25% to 38% from total net revenue of $564.2 million in 2025. The company anticipates a sharp revenue drop in early 2026 due to CMS reimbursement and coverage changes for skin substitutes, followed by stronger quarter-over-quarter growth later in the year and a return to more “normalized” growth in 2027.
Organogenesis Holdings Inc. has appointed Patrick McGuire, 40, as Chief Accounting Officer and principal accounting officer, effective February 18, 2026. His annual base salary was increased to $345,000, with no other changes to his compensation.
McGuire previously served as the company’s Vice President, Corporate Controller since September 2023 and earlier was Corporate Controller at Cynosure, LLC and a director at PricewaterhouseCoopers LLP. There are no family relationships or related-party transactions requiring disclosure. Concurrently, David Francisco ceased serving as principal accounting officer but continues as Chief Financial Officer and principal financial officer.
Organogenesis Holdings Inc. executive Lori Freedman, Chief Administrative and Legal Officer, reported multiple equity awards. She received a stock option for 115,812 shares at $0 per share, vesting in equal annual installments over four years beginning February 15, 2026. She was also granted 203,125 restricted stock units under the 2018 Equity Incentive Plan, each convertible into one share of Class A common stock, vesting annually over four years from the same date. In addition, 42,780 shares of Class A common stock were issued upon vesting and settlement of a 2025 performance share award. A separate disposition of 14,267 shares at $3.84 per share was reported to cover tax obligations by delivering shares, leaving her with 1,023,355 Class A shares directly owned after these transactions.
Organogenesis Holdings Inc. vice president Robert Cavorsi reported multiple equity awards and a related tax share disposition. He received stock options for 53,452 shares at an exercise price of $0.00 and now holds 53,452 derivative securities. He was also granted 93,750 shares of Class A common stock and a further 16,290 shares, bringing his direct Class A holdings to 276,115 shares after all transactions.
The awards include restricted stock units that vest in equal annual installments over four years beginning February 15, 2026, and options that become exercisable on the same schedule. Some shares were issued from a 2025 performance share award tied to performance milestones. A total of 5,432 shares were withheld and disposed at $3.84 per share to cover tax obligations.
Organogenesis Holdings Inc. reported that Chief Financial Officer Francisco David received equity awards and had shares withheld for taxes. He was granted a stock option for 111,358 shares with no exercise cost shown here, vesting in equal annual installments over four years beginning February 15, 2026. He also received 195,312 restricted stock units, each convertible into one share of Class A common stock as they vest annually over four years starting on the same date. In addition, 43,602 shares of Class A common stock were issued upon vesting of a 2025 performance share award tied to performance milestones, and 14,541 shares were disposed of at $3.84 per share to cover tax obligations. Following these transactions, he directly owned 731,020 Class A shares.
Organogenesis Holdings Inc. reported that Chief Commercial Officer Brian Grow received new equity awards and had shares withheld for taxes. He was granted a stock option for 133,630 shares with no exercise price shown here; the option vests in equal annual installments over four years beginning February 15, 2026.
Grow also acquired 234,375 shares and 48,330 shares of Class A common stock as equity awards, tied to restricted stock units and a performance share award that vest over time based on service and performance. In connection with the vesting of the performance award, 11,768 shares were disposed of at $3.84 per share to satisfy tax withholding obligations, leaving him with 899,355 shares of Class A common stock held directly.
Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo reported new equity awards and related tax withholding transactions. He received a stock option covering 120,267 shares of Class A common stock and was granted or issued a total of 259,549 Class A shares through stock awards on February 18, 2026.
The equity awards include restricted stock units that vest in equal annual installments over four years beginning February 15, 2026, as well as shares issued from a 2025 performance share award based on achievement of performance milestones. In a separate transaction, 16,212 shares were disposed of at $3.84 per share to cover tax obligations tied to these awards.